English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Glioblastoma (GB) is the most common and invasive brain malignancy (1), accounting for 45.2% of malignant primary and central nervous system tumors (2) and about 4% of cancer deaths worldwide. Despite combinatorial treatment of surgery, chemotherapy, and radiation therapy, the prognosis of patients with GB is still poor, with a median survival rate of only 12–15 months (3). The occurrence and development of GB are complex and reproducible diagnoses are poor, demonstrating an inability to accurately predict sensitivity or resistance to chemotherapy schemes. It is therefore necessary to understand the relevant molecular mechanisms underlying GB to improve early diagnosis, prognosis, and treatment prediction for better outcomes. MicroRNAs (miRNAs) are small endogenous singleOriginal Article

Identification of potential microRNAs in glioblastoma using bioinformatic analysis and prognostic evaluation